statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe

Unlock the latest on Royalty Pharma plc & Cytokinetics Inc.'s strategic funding collaboration for aficamten's commercialization and cardiovascular pipeline expansion.

 Latest Ratings for CYTK...

Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a $50 million milestone payment was received from Royalty Pharma plc (NASDAQ: RPRX). This milestone was triggered after the completion...

Royalty Pharma plc (NASDAQ:RPRX) Holdings Raised by Park Place Capital Corp

Park Place Capital Corp lifted its stake in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 52.2% during the fourth quarter, according to the company in its most recent disclosure with...

RPRX Makes Notable Cross Below Critical Moving Average

In trading on Wednesday, shares of Royalty Pharma plc (RPRX) crossed below their 200 day moving average of 29.00, changing hands as low as 28.68 per share. Royalty Pharma plc shares are...

January 2025 Options Now Available For Royalty Pharma (RPRX)

Investors in Royalty Pharma plc (RPRX) saw new options become available today, for the January 2025 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is...

Royalty Pharma (NASDAQ:RPRX) Stock Rating Upgraded by StockNews.com

Royalty Pharma (NASDAQ:RPRX - Get Free Report) was upgraded by StockNews.com from a "hold" rating to a "buy" rating in a research report issued on Saturday.
RPRX has been the topic of several other...

Wellington Management Group LLP Sells 748 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Wellington Management Group LLP lessened its holdings in Royalty Pharma plc (NASDAQ:RPRX  Free Report) by 0.8% in the third quarter, according to its most recent 13F filing with the...

Royalty Pharma plc (NASDAQ:RPRX) Receives $52.25 Consensus Price Target from Analysts

Royalty Pharma plc (NASDAQ:RPRX  Get Free Report) has received a consensus rating of Buy from the four analysts that are currently covering the company, MarketBeat Ratings...

Vanguard Group Inc. Purchases 589,558 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Vanguard Group Inc. increased its position in Royalty Pharma plc (NASDAQ:RPRX  Free Report) by 1.5% in the 3rd quarter, according to the company in its most recent disclosure with the...

With 70% ownership of the shares, Royalty Pharma plc (NASDAQ:RPRX) is heavily dominated by institutional owners

Key Insights Given the large stake in the stock by institutions, Royalty Pharma's stock price might be vulnerable to...

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Volume	2.5M
52-Wk High	$31.66
52-Wk Low	$25.20

RPRX Royalty Pharma plc - Ordinary Shares - Class A

About

Feed

News

Sentiment

Earnings

Fundamentals